You are here: Industry Insights > Supernus

News List

Supernus Resubmits NDA for SPN-812 for ADHD in Pediatric Patients americanpharmaceuticalreview
February 10, 2021
Supernus Pharmaceuticals has resubmitted its New Drug Application (NDA) for SPN-812 for the treatment of ADHD in pediatric patients.
Supernus Announces Positive Results from SPN-812 Study for ADHD americanpharmaceuticalreview
December 31, 2020
Supernus Pharmaceuticals has announced positive topline results from a Phase III study of SPN-812 in adults (P306) for the treatment of attention deficit hyperactivity disorder (ADHD).
Supernus Provides Regulatory Updates for SPN-812 and SPN-830 americanpharmaceuticalreview
November 20, 2020
Supernus Pharmaceuticals announced regulatory updates for SPN-812 (viloxazine hydrochloride) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age, and SPN-830 (apomorphine infusion pump) for ...
Supernus Submits SPN-830 NDA for Apomorphine Infusion Pump americanpharmaceuticalreview
September 22, 2020
Supernus Pharmaceuticals has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its apomorphine infusion pump (SPN-830) for the continuous treatment of ON-OFF episodes in adults with Parkinson’s disease (PD) ...
Supernus Completes Acquisition of CNS Portfolio from US WorldMeds americanpharmaceuticalreview
June 19, 2020
Supernus Pharmaceuticals announced the closing of the acquisition of the CNS portfolio of US WorldMeds, a privately-held biopharmaceutical company.
Supernus Acquires US WorldMeds’ CNS Portfolio contractpharma
April 30, 2020
Adds three marketed products in the U.S. and a product candidate in late-stage development.
Supernus’ stocks down once more, despite positive phase 3 ADHD data for SPN-812 fiercebiotech
December 29, 2018
Supernus Pharmaceuticals unveiled topline results from two phase 3 studies of children with attention deficit hyperactivity disorder but failed to wow investors worried about how its nonstimulant treatment would take on already-established generics.....
Supernus says ADHD drug trounces rivals, but shares slide pharmaphorum
December 10, 2018
Supernus Pharma has two phase III trials showing its attention-deficit hyperactivity disorder (ADHD) drug SPN-812 met its objectives, but still saw its shares fall as investors digested the data.
Supernus adds epilepsy candidate with $185M Biscayne buy fiercebiotech
September 18, 2018
Supernus' drug will be developed for rare childhood epilepsy disorder Dravet syndrome.